Sequence and partial functional analysis of canine Bcl-2 family proteins by de Brot, S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Sequence and partial functional analysis of canine Bcl-2 family proteins
de Brot, S; Schade, B; Croci, M; Dettwiler, M; Guscetti, F
Abstract: Dogs present with spontaneous neoplasms biologically similar to human cancers. Apoptotic
pathways are deregulated during cancer genesis and progression and are important for therapy.We have
assessed the degree of conservation of a set of canine Bcl-2 familymemberswith the human andmurine
orthologs. To this end, seven complete canine open reading frames were cloned in this family, four of
which are novel for the dog, their sequenceswere analyzed, and their functional interactionswere studied
in yeasts.Wefound a high degree of overall and domain sequence homology between canine and human
proteins. It was slightly higher than between murine and human proteins. Functional interactions between
canine pro-apoptotic Bax and Bak and antiapoptotic Bcl-xL, Bcl-w, and Mcl-1 were recapitulated in
yeasts. Our data provide support for the notion that systemsbased on canine-derived proteinsmight
faithfully reproduce Bcl-2 family member interactions known from other species and establish the yeast
as a useful tool for functional studies with canine proteins.
DOI: 10.1016/j.rvsc.2015.12.001
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-122622
Accepted Version
Originally published at:
de Brot, S; Schade, B; Croci, M; Dettwiler, M; Guscetti, F (2016). Sequence and partial functional analy-
sis of canine Bcl-2 family proteins. Research in Veterinary Science, 104:126-135. DOI: 10.1016/j.rvsc.2015.12.001
 1 
 
Sequence and partial functional analysis of canine Bcl-2 family proteins 
 
S. de Brot1, B. Schade2, M. Croci, M. Dettwiler3, F. Guscetti 
 
Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, 
Winterthurerstrasse 268, CH-8057 Zurich, Switzerland 
1Present address: School of Veterinary Medicine and Science, University of Nottingham, 
Sutton Bonington Campus, Sutton Bonington, LE12 5RD, United Kingdom 
2Present address: Department of Pathology, Bavarian Animal Health Service, Senator-
Gerauer-Str. 23, D-85586 Poing - Grub, Germany 
3Present address: Institute of Animal Pathology, Vetsuisse Faculty, University of Berne, 
Länggassstrasse 122, CH-3012 Berne, Switzerland 
 
Corresponding author: 
Franco Guscetti, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, 
Winterthurerstrasse 268, CH-8057 Zurich, Switzerland 
Email: franco.guscetti@vetpath.uzh.ch, phone: +41 44 6358595, fax: +41 44 6358934  
 2 
 
Abstract 
Dogs present with spontaneous neoplasms biologically similar to human cancers. Apoptotic 
pathways are deregulated during cancer genesis and progression and are important for 
therapy. We have assessed the degree of conservation of a set of canine Bcl-2 family 
members with the human and murine orthologs. To this end, seven complete canine open 
reading frames were cloned in this family, four of which are novel for the dog, their 
sequences were analyzed, and their functional interactions were studied in yeasts. We found a 
high degree of overall and domain sequence homology between canine and human proteins. 
It was slightly higher than between murine and human proteins. Functional interactions 
between canine pro-apoptotic Bax and Bak and anti-apoptotic Bcl-xL, Bcl-w, and Mcl-1 were 
recapitulated in yeasts. Our data provide support for the notion that systems based on canine-
derived proteins might faithfully reproduce Bcl-2 family member interactions known from 
other species and establish the yeast as a useful tool for functional studies. 
 
Key words: Bcl-2 family; canine; cloning; comparative sequence analysis; functional yeast 
study  
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1. Introduction 
 
Rodent models, including genetically modified mice and xenografts in immunocompromised 
mice, are indispensable tools for cancer research (Rosol et al., 2003; Kelland, 2004; Sharpless 
and Depinho, 2006). They have evolved in recent years to a vast array of sophisticated 
models that are continuously broadening and deepening our knowledge of cancer biology 
(Cheon and Orsulic, 2011; Ruggeri et al., 2014). A number of limitations in the use of mice, 
however, have become apparent in recent years. These limitations include the restricted 
genetic diversity inherent to mouse laboratory strains as well as substantial differences 
between humans and mice in certain molecular regulatory pathways, both factors with 
potential impact on murine tumorigenesis models (Jacks, 1996; Balmain, 2002; Hahn and 
Weinberg, 2002; Young and Longmore, 2004; Cheon and Orsulic, 2011). Xenografts in 
immunocompromised mice are widely used for preclinical drug development (Kelland, 2004) 
although these animals provide a completely different microenvironment for tumor growth 
than the original host. In addition to a limited suitability for modeling metastasis, xenograft 
models offer a "reductionist" view since the cells used represent only a small selection of all 
possible combinations of genetic and epigenetic alterations leading to a certain morphological 
tumor subtype (Sharpless and Depinho, 2006). 
Spontaneous canine neoplasms offer the opportunity to complement data from rodents. 
Cancer is the most common cause of death in dogs (Vail and MacEwen, 2000). Canines, 
similarly to humans, constitute an outbred population with a much broader genetic 
background than rodent laboratory strains. In addition, canines are genetically more closely 
related to humans than rodents as shown from whole genome comparisons of the three 
species (Lindblad-Toh et al., 2005), which is also reflected by a greater similarity at the 
metabolic level. Canines develop a range of spontaneous neoplasms often with histological 
characteristics and biologic behaviour similar to human tumors, including non-Hodgkin's 
lymphoma, soft-tissue sarcomas and osteosarcoma (Vail and MacEwen, 2000; Rosol et al., 
2003; Khanna et al., 2004). Dogs share a common environment with people. Because of their 
increasing significance as companion animals, canine tumor patients are increasingly 
subjected to therapy and hence provide a yet underexploited resource for modeling both 
pathogenetic and therapy-related aspects of human cancer. 
Deregulated apoptosis is a hallmark of cancer (Hanahan and Weinberg, 2000) and plays roles 
in tumorigenesis and the development of resistance to therapy (Johnstone et al., 2002). The 
B-cell lymphoma-2 (Bcl-2) family is a large group of proteins which exert a key regulatory 
function in intrinsic apoptosis by controlling the integrity of the outer mitochondrial 
membrane (Cory and Adams, 2002). The family encompasses three major subgroups with 
different functions and displaying different subsets of conserved sequence motifs known as 
Bcl-2 homology (BH) domains which are the hallmark of this protein family (Kelekar and 
Thompson, 1998; Daniel et al., 2003). Most anti-apoptotic members (which comprise Bcl-2, 
Bcl-xL, Bcl-w, Mcl-1 and A1) contain BH domains 1 to 4. The multidomain pro-apoptotic 
members (Bax, Bak and Bok) are required for the execution of apoptosis through the 
mitochondrial pathway (Wei et al., 2001) and contain BH domains 1 to 3 (Chan and Yu, 
2004). The third subgroup is composed of several pro-apoptotic molecules (including Bad, 
Noxa and many others) called BH3-only proteins since they display only the BH3 domain. 
They either inhibit the anti-apoptotic members or activate the multidomain pro-apoptotic 
members. Following an appropriate apoptotic stimulus, the characteristic balance between 
anti-apoptotic and multi-domain pro-apoptotic members of normal cells is perturbed. As a 
result, the complete pro-apoptotic molecules oligomerize and form channels in the outer 
mitochondrial membrane which allow the release of apoptogenic factors (e.g. cytochrome c) 
from the intermembranous mitochondrial space into the cytosol (Westphal et al., 2011). 
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Subsequently, specific proteolytic enzymes, the caspases, are activated and elicit the demise 
of the cell. The BH domains are the basis for the interactions between the members: a 
hydrophobic groove formed by specific residues of the BH1, BH2 and BH3 domains of the 
anti-apoptotic members interacts with the amphipathic helix of the BH3 domain of molecules 
of other subgroups (Cory and Adams, 2002). Comparatively little information is available, 
however, on this protein family and other molecules involved in apoptosis in canines. A small 
number of Bcl-2 family members have been cloned and partially characterized in the dog, 
including the complete coding sequences for Bcl-2, Bcl-xL, Mcl-1 and Bax (Sano et al., 2003; 
Sano et al., 2004). Differences at the molecular level within the intrinsic apoptotic pathway 
between humans and dogs have been reported in rare instances. For example, a consensus 
Akt phosphorylation site in human caspase-9 reported to mediate suppression of apoptosis is 
lacking in the dog (Cardone et al., 1998; Rodriguez et al., 2000). However, awareness of such 
variations is important because on one side they possibly impinge on the function of the 
pathway under physiological and neoplastic conditions, on the other side they may interfere 
with targeted therapies. 
The budding yeast Saccharomyces (S.) cerevisiae has been extensively used to functionally 
characterize human and murine Bcl-2 family members. Toxicity of Bax expression for yeasts 
and its abrogation by coexpression of Bcl-2, Bcl-xL and Mcl-1 first became evident in yeast 
two-hybrid studies of mammalian Bcl-2 family members (Sato et al., 1994). Subsequent 
investigations have shown that the mechanisms leading to yeast cell death caused by Bax 
partly rely on ancestral programmed cell death (PCD) machinery components (Ligr et al., 
1998; Khoury and Greenwood, 2008). Several agents can induce yeast PCD, including 
hydrogen peroxide, UV radiation, the absence of nutrients, hyperosmotic stress, acetic acid 
and aging (Farrugia and Balzan, 2012). Yeast PCD share some phenotypical and biochemical 
similarities with mammalian apoptosis, including the release of mitochondrial cytochrome c 
into the cytosol (Ludovico et al., 2002). This particular phenomenon - a hallmark of 
mammalian Bax action – has been demonstrated following Bax expression in yeast (Manon 
et al., 1997). To date, several studies of mammalian Bcl-2 family proteins in S. cerevisiae 
have focused on genetic analyses of Bax, Bcl-xL and Bcl-2, while this model has rarely been 
used, if at all, to characterize further members such as Bak, Bcl-w, and Mcl-1 for instance 
(Bodrug et al., 1995; Tao et al., 1997; Beaumont et al., 2013).  
In order to contribute to ongoing efforts in developing the canine model as a tool for cancer 
research, we herein perform an analysis of the sequences, some of which are novel for the 
dog, and study the function in the yeast, of selected canine Bcl-2 family proteins. 
 
2. Materials and methods 
 
2.1. Cell lines and cultures 
The Madin-Darby canine kidney (MDCK) cell line originates from an adult female Cocker 
Spaniel dog and it was purchased from the American Type Culture Collection (ATCC) 
(www.ATCC.org/). The cells were grown in Iscove's Mod. Dulbecco's Medium (Sigma, St. 
Louis, USA) supplemented with 10% fetal calf serum inactivated at 60°C, 2.5% HEPES 
buffer (Sigma, St. Louis, USA), 1% L-Glutamine (Sigma, St. Louis, USA) and 1% Penicillin-
Streptomycin solution (Sigma, St. Louis, USA). The canine normal keratinocyte line used 
originates from the skin of a healthy Beagle dog (Kolly et al., 2005). The cells were grown in 
Dulbeccos' Modified Eagles Medium (Sigma, St. Louis, USA) supplemented with 1% non-
essential amino acids, 1% sodium pyruvate, 1% penicillin/streptomycin and 15% fetal calf 
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serum. All cell culture reagents were obtained from Gibco BRL life Sciences (Basel, 
Switzerland). Both cell lines were grown at 37 °C and a 5% CO2 atmosphere. 
 
2.2. RNA extraction, RT-PCR and cloning 
Total RNA was isolated from MDCK cells and/or from normal canine keratinocytes with the 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocols. Then 
40 U Protector RNAse Inhibitor (Roche, Mannheim, Germany) was added to each RNA 
extract. cDNA was synthesized from 1µg of total RNA using the 1st strand cDNA Synthesis 
Kit for RT-PCR (AMV) and an oligo-dT-primer according to the manufacturer's instructions 
(Roche, Mannheim, Germany).  
Primers including the putative Start and Stop codons as deduced from publicly available 
sequence information and taking the human sequence as a reference (Tables 1 and 2) were 
designed either manually or by using the Primer3 website (http://frodo.wi.mit.edu/) (Rozen 
and Skaletsky, 2000). Reverse transcription PCR reactions were accomplished with 1µl of 
cDNA samples and Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, 
USA). Basic cycling parameters were as follows: initial denaturation at 94 °C for 1.5 min; 35 
cycles of denaturation at 94 °C for 50 sec, annealing for 50 sec at 50-70 °C (a gradient was 
chosen on dependance of the primer melting temperature) and extension at 72 °C for a time 
adjusted to the expected size of the product (1 min per 1000 bp); final extension for 10 min at 
72 °C. Each PCR reaction was optimized by adjusting the annealing temperature and the final 
magnesium concentration to yield a band with the size corresponding to the expected 
principal transcript for each molecule. After agarose gel separation, the amplificates obtained 
were recovered with MinElute Gel Extraction Kit (Qiagen, Hilden, Germany) and sent to a 
company (Microsynth AG, CH-9436 Balgach) for direct sequencing (Cycle Sequencing / 
Capillary Electrophoresis) with the primers used for amplification. If the amplification 
product corresponded to the expected sequence, the PCR was repeated using primers 
containing restriction enzyme sites suitable for cloning into the GST-tagged pGEX-4T2 
vector (Invitrogen, Carlsbad, USA). Amplicons were cloned and transformed into DH5 alpha 
competent cells. Miniprep plasmid DNA was sequenced (Microsynth AG, CH-9436 Balgach) 
using the pGEX 5'- and 3'-sequencing primers indicated by the manufacturer. Final cDNA 
sequences were derived from the consensus of at least three individual clones and were 
deposited in GenBank (Table 2). The correct identity of the clones was further confirmed at 
the protein level with immunoblot analyses with appropriate antibodies using lysates of 
transformed BL-21 Star E. coli harvested after induction with beta-D-thiogalactopyranoside 
as previously described by Keller et al. (2007). 
 
2.3. Computational analysis 
Putative canine protein sequences were derived from the cDNA sequences using a translation 
tool accessed via the ExPASy homepage (http://www.expasy.org/). Canine nucleotide coding 
sequences (cds) and deduced protein sequences were compared with human and murine 
counterparts (Table 2) using the EMBOSS sequence analysis tool provided by the European 
Bioinformatics Institute (http://www.ebi.ac.uk/emboss/align/). The nucleotide and the protein 
sequences were aligned with the needle method and the Blosum62 matrix algorithm, 
respectively. The exon/intron structure was derived by aligning the cds with the respective 
genome sequence using Splign, a mRNA-to-genomic alignment program available at NCBI 
(http://www.ncbi.nlm.nih.gov/) and confirmed using BLAT (Blast like alignment tool) on the 
MGC genome browser (http://mgc.ucsc.edu/) (Kent, 2002). The genomic sequence releases 
were CanFam3.1 [GCF_000002285.2] for canines, Mus musculus GRCm38.p1 
[GCF_000001635.21] for murines, and [GCF_000001405.22 GCF_000306695.1 
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GCF_000002135.2 GCF_000002125.1] for humans. For domain comparisons we used 
human domain signatures indicated in UniProtKB/Swiss-Prot and additional relevant features 
as suggested from the literature.  
 
2.4. Subcloning and expression in S. cerevisiae 
The cDNAs containing the cds for the canine multidomain pro-apoptotic proteins Bax and 
Bak and the anti-apoptotic proteins Bcl-xL, Bcl-w, and Mcl-1 were subcloned by sticky-end 
ligation in a yeast expression vector (epitope tagging vector pESC, Invitrogen) containing the 
URA3 selection marker. This vector contains two multiple cloning sites which are located 
downstream of the galactose inducible divergent promoters GAL1 and GAL10, respectively. 
Each cDNA was introduced individually in the vector. In addition, vectors were constructed 
with Bax or Bak paired with each one of the cDNAs for the anti-apoptotic proteins. Proper 
introduction of the cDNAs was verified by sequencing (Microsynth AG, CH-9436 Balgach) 
miniprep plasmid DNA using the pESC 5'- and 3'-sequencing primers indicated by the 
manufacturer. The yeast used throughout this study was strain BY4743 
Δhis3/leu2/met15/ura3 purchased from Euroscarf (D-60438 Frankfurt; Acc. No. Y20000). It 
was routinely cultured in YPAD (1% yeast extract, 2% Bacto peptone, 2% glucose, 40 mg 
Adenine sulfate) medium as described (Guscetti et al., 2005). The yeasts were transformed by 
electroporation in presence of 1 M sorbitol (Gene Pulser with Pulse Controller, Bio-Rad) 
according to a previously described protocol (Becker and Lundblad, 1994) with the empty 
plasmid and all plasmids described above. Selection was done on minimal 2% glucose 
medium without the selection marker URA. To monitor the effect of expression of the Bcl-2 
family proteins, transformed yeasts were grown under aerobic conditions (shaken at 220 rpm, 
30 °C) in 3 ml of liquid minimal medium containing 2% galactose (inducing) instead of 
glucose (repressing) and the optical density at 600 nm (OD600) was measured every 6 hours 
until saturation. Each experiment was carried out in duplicate. In addition, a clonogenic assay 
was carried out by plating aliquots of 500 cells on minimal glucose medium, each in 
triplicate, after growth in inducing liquid medium for 24 and 48 hours as previously described 
(Guscetti et al., 2005). All clonogenicity experiments were carried out at least in three 
independent instances. Statistical significance of clonogenicity data for yeasts expressing 
either Bax or Bak alone vs. all other proteins either individually or in combination was 
calculated by the student´s t test. Significance was set at a value of p = 0.05. 
 
2.5. Western Blots 
To verify expression of the respective protein after induction, representative culture samples 
collected at 24h or 48h after start of induction were analysed by western blot as previously 
described with minor modifications (Dettwiler et al., 2013). Briefly, protein extracts were 
prepared by mechanical lysis of the yeast cells (mixed to equal volumes of a lysis buffer 
containing 100 mM Tris-HCl at pH 6.8, 10% (v/v) glycerol, 3% (w/v) SDS, 5% (v/v) 2-
mercaptoethanol and 1% (w/v) bromophenol blue using glass beads and a Vortex mixer at 
maximum speed for 2 min. The extracts were run on 12% SDS-polyacrylamide gels, 
transferred to PVDF membranes (Immobilon-P Transfer Membrane, Millipore Corporation, 
Billerica, MA) by electroblotting. Following primary antibodies, all previously shown to 
cross-react with the recombinant canine protein expressed in bacteria, were used: anti-human 
Bax Ab-1 mouse monoclonal antibody, clone 2D2 (cat. no. MS-711-P0, Lab Vision 
Corporation, Thermo Fisher Scientific, Fremont, CA 94539, USA), applied at 0.5 ug/ml; anti-
human Bak rabbit polyclonal antibody (cat. no. 06-536, Merck Millipore, Billerica, MA 
01821, USA), applied in a 1:400 dilution; anti-mouse Bcl-xL Ab-2 mouse monoclonal 
antibody, clone 7D9 (cat. no. MS-1334-PO, Lab Vision Corporation, Thermo Fisher 
Scientific, Fremont, CA 94539, USA), applied at 0.5 ug/ml; anti-human Bcl-w (16-29) rabbit 
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polyclonal antibody (cat. no. 197209, Merck Chemicals Ltd., San Diego, CA 92121, USA), 
applied in a 1:400 dilution; and anti-human Mcl-1 rabbit polyclonal antibody (cat. no. 
HPA008455-100UL, Atlas Antibodies AB, SE-106 91 Stockholm, Sweden), applied in a 
1:400 dilution. After incubation with the appropriate primary antibodies, horseradish-
peroxidase labelled secondary antibodies were applied and binding was visualised using a 
chemiluminescent substrate.	  The PageRulerTM Plus Prestained Protein Ladder (Fermentas 
Life Sciences, Lot 00070238; Thermo Fisher Scientific, Fremont, CA 94539, USA) was used 
to assess protein sizes. 
 
3. Results 
 
3.1. Nucleotide sequence comparison of canine Bcl-2 family members with the human and 
murine orthologues 
We have identified and cloned the coding sequence (cds) of seven canine Bcl-2 family 
members. Three sequences (Bcl-x, Bax and Mcl-1) have previously been reported by others 
(Sano et al., 2003; Sano et al., 2004), the remaining four (Bcl-w, Bak, Bad and Noxa) are 
novel for the dog and have been deposited in GenBank. All sequence accession numbers are 
indicated in Table 2. In this section we report basic data derived from our cDNA clones, and, 
for the sake of completeness, from the complete mRNA sequence for canine Bcl-2 previously 
deposited in GenBank by others. Alignment of the sequences with the dog genome showed 
100% identity and canonical splice sites except where otherwise stated. Expected amino acid 
exchanges resulting from base mismatches are mentioned. In addition, a comparison with the 
reference sequences of the human and murine counterparts is presented (Table 3). 
Bcl-2 isoform α.  The canine complete mRNA sequence for Bcl-2 available from GenBank 
was derived from peripheral mononuclear blood cells of an adult dog. The dog genome 
sequence displays a gap in the region containing the Bcl-2 gene resulting in 102 bases of the 
cds (from base 157 through 258) that could not be aligned. Mismatches were observed at 
positions 146 (T instead of C as in the genome sequence, resulting in a Phe instead of a Ser), 
148 (T instead of G, resulting in a Ser instead of an Ala), 327 (C instead of G), 330 (C instead 
of T) and 441 (T instead of C) of the cds. In addition a single base insertion was found at 
position 331 (G, eliciting a frame shift) of the cds. Comparison with the human Bcl-2 isoform 
α cds (720 bp) revealed 92% identity for the canine sequence (720 bp) which is close to the 
homology observed between human and murine (711 bp) sequences (89%).  
Bcl-xL (BCL2L1).  The complete mRNA sequence for the canine anti-apoptotic Bcl-2 family 
member Bcl-xL available in GenBank was derived from lymphocytes of an adult dog. All our 
own clones (source: MDCK cells) showed a single nucleotide mismatch (C instead of T) at 
position 666 of the cds when compared to the GenBank sequence. The dog genome reference 
sequence indicates a C at this position. In all three species, the Bcl-xL cds (702 bp) is 
distributed over two exons. Overall, canines show a slightly higher homology with humans 
than with mice (97% and 94%, respectively).  
Bcl-w (BCL2L2).  The cds of the canine anti-apoptotic Bcl-2 family member Bcl-w generated 
in this study (source: MDCK cells) is, like the human and murine cds, 582 bp long and 
distributed over two exons. The identity of the canine Bcl-w cds with its human counterpart is 
95%, while the identity between human and mouse is 94%. 
Mcl-1.  The complete mRNA sequence for the canine anti-apoptotic Bcl-2 family member 
Mcl-1 available in GenBank was derived from lymphocytes. Alignment of this sequence with 
our Mcl-1 cds (source: MDCK cells) showed a one base deletion, a one base insertion and 
four single nucleotide mismatches. Alignment of our sequence with the dog genome 
indicated one nucleotide mismatch at position 436 (C instead of T) in our sequence. 
Alignment of the GenBank cds with the dog genome revealed a single bp insertion at position 
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31 and a single base deletion 9 bp further on as well as five mismatches at positions 6 (T 
instead of C), 119 (G instead of A), 436 (C instead of T), 641 (A instead of G) and 978 (C 
instead of T). Two of these mismatches would lead each to a amino acid (aa) substitution 
(position 119: Arg instead of Lys; position 641: Gln instead of Arg), the latter involving the 
BH3-domain. The insertion at position 31 leads to a short frameshift resulting in the 
exchange of aa 11-13 (Arg-Thr-Gln instead of Gly-Leu-Asn); this region does not code for 
any known domain. In both humans and dogs, the Mcl-1 cds encompasses 1053 bp, in 
contrast to 996 bp in mice. In all three species investigated, the cds is distributed over three 
exons. The canine cds shares a higher homology with the human counterpart than the murine 
sequence (89% and 83% identity, respectively). 
Bak (BAK1).  The cds of the canine multi-domain pro-apoptotic Bcl-2 family member Bak 
generated in this work (source: MDCK cells) consists, like its human counterpart, of 636 bp 
distributed over five exons. The murine cds is six bp shorter (630 bp). The human sequence is 
more similar to the canine than to the murine sequence (90% and 80% identity, respectively).  
Bax variant α.  The mRNA sequence comprising the complete cds of Bax available in 
GenBank was derived from a canine osteosarcoma cell line. Our own cds sequence is 100% 
identical to the GenBank sequence. The dog genome sequence displays a gap in the region 
containing the bax gene; where proper alignement was possible (position 1 through 477 of the 
cds) our sequence (source: MDCK cells) was 100% identical to the genome sequence. In all 
three species investigated, the cds is 579 bp long. In murines and humans it is distributed over 
six exons. The cds of both dogs and mice show a similar degree of homology with the human 
Bax var. alpha (93% and 90% identity, respectively). We additionally detected a splice form 
of the canine Bax cds, which is similar to the human Bax γ version (GenBank accession no. 
NM_138762). Like its human counterpart, the cds consists of 126 bp divided into two exons. 
It shares 91% identity with the human Bax γ cds. In silico translation predicts, like in humans, 
an hypothetical protein of 41 aa (identity human/canine: 83%). 
Bad.  The cds of the canine BH3-only Bcl-2 family member Bad generated from MDCK cells 
in this study consists of three exons, spanning 504 bp in length. This is three bp shorter than 
the human cds and 111 bp shorter than the murine cds, which spans over four exons. Since 
several gaps occur in the alignment between human and canine cds, we generated additional 
clones from a normal canine keratinocyte cell line (Kolly et al., 2005) to exclude a MDCK-
related artifact. Clones from both cell types yielded the same sequence. The canine Bad cds is 
86% identical to its human counterpart, whereas the identity between human and mouse is 
only 65%, due to the additional coding exon at the 5'-end in the murine sequence. When only 
overlapping parts were compared, identity between human and mouse sequences was 82%. 
Noxa (PMAIP1).  The cds of the canine BH3-only Bcl-2 family member Noxa, generated 
from a normal canine keratinocyte cell line (Kolly et al., 2005) in this study, is distributed, 
like its human counterpart, over two exons with a total of 165 bp. It yields 87% identity with 
the human sequence. The murine cds is divided into three exons and spans 312 bp. The 
mouse sequence differs remarkably from the human (40% identity), which ensues from the 
presence of an additional coding exon at the 5'-end in the murine sequence. Comparison of 
overlapping parts only yielded 70% identity between human and mouse sequences. 
 
3.2. Protein sequence comparison of canine Bcl-2 family members with the human and 
murine orthologues 
We further analyzed in silico the protein sequences of the canine Bcl-2 members as deduced 
from the nucleotide sequences described above. The degree of conservation between humans, 
canines and mice of the whole proteins as well as of the most relevant domains, motifs and 
residues were determined (Table 4). All sequences and respective alignments are reported in 
Supplemental Figure 1.  
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The overall identity of these proteins ranged from 76% to 100% between canines and 
humans, and from 34% to 99% between mice and humans. In all but one (Bcl-2 isoform 
alpha)cases there was a higher degree of homology between human and canine sequences 
than between human and murine sequences. The length of the Bcl-2 family proteins is 
relatively conserved in canines compared to humans, while it markedly differs for some 
murine proteins, in particular the BH3-only members Bad and Noxa. The anti-apoptotic 
family members are best conserved, with the two proteins Bcl-xL and Bcl-w 100% identical at 
the amino acid (aa) level between humans and dogs. In murines, three out of 15 Bcl-2 
Homology (BH) domains analyzed in this subgroup differed from the human counterpart by 
one aa, while there were no differences in dogs. The transmembrane domains showed either 
100% conservation in all three species (Bcl-xL, Bcl-w, Mcl-1) or slight differences with the 
human counterpart in the canine version (Bcl-2). The multi-domain pro-apoptotic members 
Bak and Bax showed a slightly lower degree of interspecies conservation than the anti-
apoptotic members. In the mouse, all BH domains of these two molecules showed at least one 
aa exchange, three BH domains showed two aa exchanges. In the dog only two out of these 
six BH domains showed one aa exchange. The transmembrane domain of Bax is 100% 
conserved across the three species, that of Bak shows an exchange of four aa in mice and of 
two aa in dogs. Interestingly, the lowest overall and domain identity in the Bcl-2 family was 
observed with the two BH3-only proteins Bad and Noxa. This is particularly true for the 
murine molecules which are markedly longer than the canine and human counterparts. 
Comparison of these proteins between murines and humans yielded 58% and 34% identity 
for Bad and Noxa, respectively (while their overlapping regions showed 73% and 64% 
identity, respectively). 
Several human Bcl-2 family proteins present with cleavage sites for caspase-3 and other 
proteases. Figure 1 shows the comparative tetramer sequences preceding cleavage sites 
reported in the literature. Sequences 100% conserved in all three species include both 
caspase-3 cleavage sites of Bcl-xL, the major caspase-3 cleavage sites of Mcl-1 and of Bad, 
and the calpain recognition sequence of Bax (Cheng et al., 1997; Clem et al., 1998; Fujita et 
al., 1998; Wood et al., 1998; Condorelli et al., 2001; Michels et al., 2004). 
 
3.3. Partial functional characterization of canine Bcl-2 family proteins in the yeast S. 
cerevisiae 
In this part we functionally analyzed interactions of a subset of canine Bcl-2 family members 
comprising the multidomain pro-apoptotic proteins Bax and Bak and the anti-apoptotic 
proteins Bcl-xL, Bcl-w and Mcl-1 in the yeast model S. cerevisiae. First, the proteins were 
expressed in inducing liquid media containing galactose, and yeast cell growth was 
monitored by measuring the OD600 at 6 h intervals. As expected, compared to yeasts 
containing the empty vector, cultures of yeasts expressing either Bax or Bak showed a growth 
delay, while the growth of yeasts expressing any of the anti-apoptotic proteins was unaffected 
(Fig. 2a). The growth delay caused by Bax or Bak was completely abrogated when any of the 
anti-apoptotic proteins was expressed concomitantly (Fig. 2b). This kind of growth delay has 
previously been described for human and/or murine Bax and Bak, and it has been attributed 
to reproductive cell death (Ligr et al., 1998; Xu et al., 1999; Guscetti et al., 2005). This notion 
was herein confirmed for the canine orthologs by using a clonogenic assay following 24 and 
48 hours of protein expression. The data is presented in Fig. 3a and 3b. Expression of either 
Bak or Bax alone resulted in a reduction of the percentage of viable and reproduction-
competent yeasts to 20-10% (Bak) or 3-1% (Bax) of yeasts carrying the empty vector. In 
contrast, Bcl-xL and Mcl-1 showed a slight degree of toxicity which was most apparent at 48 
h of expression (Fig. 3b). The effect of Bax and Bak was abrogated through concomitant 
expression of each of the anti-apoptotic proteins Bcl-w, Bcl-xL, and Mcl-1. Extracts from 
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yeasts transformed with the corresponding cDNAs showed distinct bands for each protein in 
Western blots indicating their expression (Fig. 4). 
 
4. Discussion 
 
We have carried out a comparative sequence analysis of a representative number of canine 
Bcl-2 family members, at both the nucleotide and protein level. A high sequence homology 
was found between the canine proteins and their human and murine counterparts. Notably, 
the canine sequences showed a higher degree of homology with the human sequences than 
the murine sequences, which is consistent with a faster mutation rate in mice as compared to 
dogs and people (Lindblad-Toh et al., 2005) and supports in principle the dog as a model 
organism for diseases involving deregulation of mitochondrial apoptosis. Bcl-2 family 
proteins have been assigned a central importance in the pathogenesis of various human 
cancer syndromes (Kelly and Strasser, 2011; Nys and Agostinis, 2012). Likewise, they have 
been implicated in the pathogenesis of diverse canine tumors including for instance 
hemangiosarcoma, mammary tumors, tumors of neural and hematopoetic origin (Sano et al., 
2003; Kumaraguruparan et al., 2006a; Kumaraguruparan et al., 2006b; Yan et al., 2006; 
Murakami et al., 2008; Ide et al., 2010; Strefezzi et al., 2012; Dettwiler et al., 2013).  
Proteins are assigned to the Bcl-2 family owing to the presence of at least one of four BH 
domains (Kelekar and Thompson, 1998; Daniel et al., 2003). These domains mediate the 
interplay between the Bcl-2 family members, which controls the integrity of the 
mitochondrial membrane. Structural studies have shown the basis for interactions between 
the different subgroups (Cory and Adams, 2002). The fact that several domains participate in 
forming a functionally important scaffold-like structure might explain the limited overall and 
domain interspecies variation found in anti-apoptotic members of the Bcl-2 family. In 
contrast, the BH3-only members Bad and Noxa showed the least degree of overall 
interspecies conservation. This might derive from the fact that the BH3-only subgroup 
members exert their apoptosis-related function through one single domain as opposed to 
members of the other subgroups. Both murine Bad and Noxa significantly differ from their 
human and canine counterparts by displaying an additional coding exon. In addition, murine 
Noxa displays a second BH3-domain motif (Oda et al., 2000). In contrast, regulatory serine 
residues (Ser 75, 99, 118, 134 in humans) in Bad are conserved among the three species at nearly the 
same locations. Phosphorylation of these residues upon a pro-survival stimulus maintains Bad 
in an inactive state and bound to cytosolic 14-3-3Sigma proteins (Bae et al., 2001). Recent 
studies have revealed that the anti-apoptotic members of the Bcl-2 family each bear a unique 
pattern of interaction with peptides derived from BH3 domains of BH3-only molecules 
(Certo et al., 2006) providing the basis for the development of therapeutic compounds 
targeting these interactions (Liu and Wang, 2012). The strong degree of conservation of the 
dog proteins suggest that this species is potentially well-suited for modeling interactions of 
Bcl-2 family members and related therapeutic peptides.  
Apoptosis is executed through cleavage of proteins at specific recognition sites through 
specific proteases, mainly through caspases (Cory and Adams, 2002). Several members of the 
Bcl-2 protein family display protease cleavage sites, and their cleavage products have been 
shown in general to enhance apoptotic activity (Cheng et al., 1997; Clem et al., 1998; Fujita 
et al., 1998; Wood et al., 1998; Condorelli et al., 2001; Michels et al., 2004) and in some 
cases to mediate apoptotic activity (Ofengeim et al., 2012). Sequence comparison between 
human, canine and murine Bcl-2 family members has revealed a number of fully conserved 
cleavage sites. Some of the remaining cleavage sites conserved to less than 100%, such as 
e.g. the motif present in canine Bcl-2, might still be functional based on the sequence, while 
others, such as for example the minor cleavage site of Bad, are likely not functional. The 
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impact of sequence variants on function should be verified experimentally. Conservation of 
protease recognition motifs across species support their biological relevance on one side and 
the validity of the canine model on the other side. 
Comparison of the sequences generated in this study with the canine genome sequence as 
well as with mRNA sequences previously submitted to Genbank by others revealed a 
generally high degree of concordance. Except for the gap in the genome sequence in the 
region coding for Bax and for a single base mismatch in the cds of Mcl-1 all sequences 
generated in this study (4119 bases) were 100% identical with the dog genome sequence. 
Another gap in the genome sequence hindered proper alignment of the Bcl-2 cds available 
from Genbank. Nevertheless, the dog genome third release coverage has been estimated at 
99.8% of the euchromatic portion of the genome, and the rate of sequencing errors within 
genes has been drastically reduced compared to the previous release (Lindblad-Toh et al., 
2005; Hoeppner et al., 2014). Mismatches either represent sequencing errors, single 
nucleotide polymorphisms, somatic cell variation, or RNA editing (Furey et al., 2004). All of 
our novel cds were also predicted by the automated prediction program GNOMON at NCBI 
with the exception of Noxa. In addition, the automated program predicted an additional 
sequence at the 5'-end of canine Bad that was not supported by own 5'-RACE data (data not 
shown). Comparisons of previous GenBank entries with the dog genome revealed 
conspicuous mismatches for Bcl-2 and Mcl-1. An analysis of approximately 30,000 non-
redundant human mRNA sequences suggested that mRNA collections may contain a 
substantial number of errors (Furey et al., 2004). 
We have used the well-characterized eukaryotic yeast S. cerevisiae for the expression and 
functional analysis of the canine Bcl-2 proteins cloned herein. This unicellular organism is 
easy to manipulate genetically and it has previously been extensively used for functional 
studies of human Bcl-2 family proteins since considered to be devoid of homologs of the Bcl-
2 family (Fleury et al., 2002; Priault et al., 2003; Guscetti et al., 2005; Khoury and 
Greenwood, 2008). This notion has recently been questioned since the description of a yeast 
protein variously referred to as Bxi1p (Bax inhibitor-1) or Ybh3p (Yeast BH3-only protein) 
(Büttner et al., 2011; Cebulski et al., 2011). However, while its classification and function are 
still debated, it did not visibly interfere with the experiments in this study. Expression of 
canine Bcl-2 family members in yeast has not been described before. Here, we successfully 
performed a functional analysis of five canine Bcl-2 family members in this model organism, 
namely the pro-apoptotic members Bak and Bax and the anti-apoptotic members Bcl-w, Bcl-
xL and Mcl-1. As previously described for the human and/or murine orthologs (Ink et al., 
1997; Tao et al., 1997; Ligr et al., 1998), expression of canine Bak and Bax showed a lethal 
effect in yeast. Moreover, this effect was abrogated on co-expression of the anti-apoptotic 
members Bcl-xL, Mcl-1 and Bcl-w as previously demonstrated for large part of their human 
orthologs in yeast (Tao et al., 1997; Beaumont et al., 2013). To our knowledge, abrogation of 
the effect of Bak by Bcl-w has not been previously reported in this model. We therefore 
consider the yeast system as suitable for the functional assessment of canine Bcl-2 family 
members and their interactions. Future use of the model could encompass e.g. the addition of 
BH3-only proteins (Guscetti et al., 2005) or the comparative exploration of the effects of 
specific compounds on interactions between Bcl-2 family members of canine versus human 
origin (Silva et al., 2011) thus further assessing the potential value of the canine model. 
Several murine models, in particular genetically engineered mouse models, have proven 
invaluable for mechanistic and drug discovery studies (Cheon and Orsulic, 2011; Ruggeri et 
al., 2014). As a specific example, the Eµ-myc lymphoma model has been successfully used to 
model the efficacy of the Bcl-2 antagonist ABT-737 against an aggressive lymphoma subtype 
(Mason et al., 2008), and its derivative ABT-199 is currently tested in phase II and III studies 
(Besbes et al., 2015). Provided the canine and human molecules behave similarly, 
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spontaneous dog tumors could provide an additional frame for testing such compounds in a 
clinical setting. 
 
5. Conclusions 
 
In summary, we have performed a comparative as well as a functional analysis of a 
representative set of canine Bcl-2 family members. Our analysis revealed a high degree of 
sequence similarity in the canine Bcl-2 family proteins compared to their human 
counterparts, especially within domains. Functional interactions of selected canine 
multidomain pro-apoptotic with anti-apoptotic members were recapitulated in a yeast model. 
This in vitro model might provide a valuable tool for instance for testing therapies 
specifically targeting this protein family and, subsequently, to further establishing 
spontaneous dog neoplasms as models for human cancer. 
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Figure legends 
 
Fig. 1  Interspecies conservation of protease (caspase and calpain) recognition motifs in 
indicated Bcl-2 family members.  
 
Fig. 2  Growth curves of yeast expressing Bcl-2 family proteins grown in minimal inducing 
medium. A: expression of proapoptotic proteins Bak and Bax impose marked growth 
retardation. B: co-expression of anti-apoptotic Bcl-2 family proteins abrogates the growth 
retardation effect of Bak and Bax. The curves are deduced from OD600 measurements at 6h 
intervals and are representative of two independent experiments. 
 
Fig. 3  Clonogenic assay of yeast cultures induced to express different Bcl-2 family proteins 
by growth in liquid galactose media for 24h (a) and 48h (b), followed by plating on non-
inducing, glucose containing, solid media, and growth for 72h at 30 °C. The columns indicate 
the mean value and standard error of the mean (SEM) of at least three independent 
experiments. Expression of Bak and Bax results in massively reduced clonogenicity. This 
effect is more pronounced after protein expression of 48h (b) compared to 24h (a) and is 
abrogated by co-expression of anti-apoptotic proteins. Values for Bax and Bak are 
significantly different from all other values (** p<0.0001, *P=0.019, student’s t test). 
 
Fig. 4  Western blots of yeasts transformed with plasmids containing the indicated canine 
Bcl-2 family cDNAs, cultured in liquid inducing medium for 24 h and labelled with the 
indicated antibodies. Relevant marker sizes are indicated. (a): lane 1, vector only; lane 2, Bcl-
w; lane 3, Bcl-w+Bak; lane 4, Bcl-w+Bax; lane 5, Bcl-x+Bak; lane 6, Bcl-x+Bax, lane 7, 
Mcl-1+Bak; lane 8, Mcl-1+Bax. (b): lane 1, vector only; lane 2, Bcl-w. (c): lane 1, vector 
only; lane 2, Bcl-x. (d): lane 1, vector only; lane 2, Mcl-1. 
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Figure 2a 
 
Figure 2b 
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Figure 3a 
 
Figure 3b 
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Figure 4 
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Table 1.  Primers for amplification of canine Bcl-2 family cDNAs 
      
Molecule Forward primer Reverse primer 
      Bcl-xL (BCL2L1) 5`-CCATCCCTATTATAAAAATGTCTCA-3` 5`-GGGTAAGTGGGTGGTCAGTG-3` * 
Bcl-w (BCL2L2) 5`-GGATGGCGACCCCAGCC-3` 5`-GCTCACTTGCTCGCAAAAAAG-3` 
Mcl-1 5`-AGGAGCTTGCGATGTTCGG-3` 5`-CACTTAAAAGGCTATCTTATTAG-3` 
Bak 5`-GAGAAATGGCATCCGGGC-3` 5`-CCTCTGGGAGTCATGATTTG-3` 
Bax var. alpha 5`-TGATGGACGGGTCCGGGG-3` 5`-GGCCTCAGCCCATCTTTTTC-3` 
Bad 5`-AGAGCATGTTCCAGATCCC-3` 5`-GGACGCGGGACGGGTCAC-3` 
Noxa (PMAIP1) 5`-AGATGCCCGGCCGGAAG-3` 5`-ATCAAGGTTCCTGAGCGGAAG-3` 
      
Start- and stop-codons are indicated in bold 
 * Stop-codon is upstream of primer sequence 
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Table 2.   Accession numbers of Bcl-2 family members used in this study 
        
 
Nucleotide and protein sequence accession number for indicated species  
Molecule Human1 Canine2 Murine1 
        
    Bcl-2 isoform alpha NM_000633.2, NP_000624.2 AB154172.1, BAD05044.1  NM_009741.4, NP_033871.2 
Bcl-xL(BCL2L1) NM_138578.1, NP_612815.1 AB073983.1, BAB71819.1 NM_009743.5, NP_033873.3 
Bcl-w (BCL2L2) NM_004050.4, NP_004041.1 DQ116955.13, AAZ22484.13 NM_007537.1, NP_031563.1 
Mcl-1 NM_021960.4, NP_068779.1 AB093582.2, BAC21258.1 NM_008562.3, NP_032588.1 
Bak NM_001188.3, NP_001179.1 DQ002813.13, AAY19401.13 NM_007523.2, NP_031549.2 
Bax variant alpha NM_138761.3, NP_620116.1 AB080230.1, BAC53619.1 NM_007527.3, NP_031553.1 
Bad NM_004322.3, NP_004313.1 DQ127247.13, AAZ32936.13 NM_007522.3, NP_031548.1 
Noxa (PMAIP1) NM_021127.2, NP_066950.1 DQ449072.13, ABE02691.13 NM_021451.2, NP_067426.1 
        
    1Reference Sequences available at NCBI 
2GenBank accession numbers 
3Own submission 
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Table 3.  Interspecies comparison of Bcl-2 family 
members coding sequences  
              
Molecule 
No. of coding 
exons  
Coding sequence 
identity 
Hu Ca Mu   Hu / Ca Hu / Mu 
       Bcl-2 isoform alpha 2 ? 2  92% 89% 
Bcl-xL (BCL2L1) 2 2 2  97% 94% 
Bcl-w (BCL2L2) 2 2 2  95% 94% 
Mcl-1 3 3 3  89% 83% 
       Bak 5 5 5  90% 80% 
Bax variant alpha 6 ? 6  93% 90% 
       Bad 3 3 4  86% 65% 
Noxa 2 2 3  87% 40% 
              
       Hu: human; Ca: canine; Mu: murine 
    ?: alignment to genome sequence incomplete 
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Table 4.  
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Supplemental Figure S1 
 
Alignments of Bcl-2 proteins of human, canine, and murine origin and principal domains and 
motifs 
 
Alignment for Bcl-2 isophorm alpha 
 
 
Human   1 MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPA    60 
Canine   1 MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGEAGAAPPGAAPAPGIFSSQPGRAPAP-    59 
Murine   1 MAQAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDADAAPLGAAPTPGIFSFQPESNPMPA    60 
 
 
Human  61 ASRDPVARTSPLQTPAAPGA-------AAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFA   113 
Canine  60 ------ARTSPPPPPAAPAAAAAAAADAAGPAPSPVPPVVHLTLRQAGDDFSRRYRRDFA   113 
Murine  61 VHRDMAARTSPLR-PLV--A-------TAGPALSPVPPVVHLTLRRAGDDFSRRYRRDFA   110 
 
 
Human 114 EMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNI   173 
Canine 114 EMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNI   173 
Murine 111 EMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNI   170 
 
 
Human 174 ALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLG  233 
Canine 174 ALWMTEYLNRHLHTWIQDNGGWDAFVELYGPTMQPLFDFSWLSLKALLSLALVGACITLG  233 
Murine 171 ALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLG  230 
 
 
Human 234 AYLGHK  239 
Canine 234 AYLGHK  239 
Murine 231 AYLGHK  236 
 
Alignment for Bcl-xL (BCL2L1) 
 
 
Human   1 MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLA    60 
Canine   1 MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLA    60 
Murine   1 MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEETEAERETPSAINGNPSWHLA    60 
 
 
Human  61 DSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAY   120 
Canine  61 DSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAY   120 
Murine  61 DSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAY   120 
 
 
Human 121 QSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEP   180 
Canine 121 QSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEP   180 
Murine 121 QSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIASWMATYLNDHLEP   180 
 
 
Human 181 WIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK  233 
Canine 181 WIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK  233 
Murine 181 WIQENGGWDTFVDLYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK  233 
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BH1 
BH2 TM 
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BH3 
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TM BH2 
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(Supplemental Figure S1 ctd.) 
 
Alignment for Bcl-w (BCL2L2) 
 
 
Human   1 MATPASAPDTRALVADFVGYKLRQKGYVCGAGPGEGPAADPLHQAMRAAGDEFETRFRRT    60 
Canine   1 MATPASAPDTRALVADFVGYKLRQKGYVCGAGPGEGPAADPLHQAMRAAGDEFETRFRRT    60 
Murine   1 MATPASTPDTRALVADFVGYKLRQKGYVCGAGPGEGPAADPLHQAMRAAGDEFETRFRRT    60 
 
 
Human  61 FSDLAAQLHVTPGSAQQRFTQVSDELFQGGPNWGRLVAFFVFGAALCAESVNKEMEPLVG   120 
Canine  61 FSDLAAQLHVTPGSAQQRFTQVSDELFQGGPNWGRLVAFFVFGAALCAESVNKEMEPLVG   120 
Murine  61 FSDLAAQLHVTPGSAQQRFTQVSDELFQGGPNWGRLVAFFVFGAALCAESVNKEMEPLVG   120 
 
 
Human 121 QVQEWMVAYLETRLADWIHSSGGWAEFTALYGDGALEEARRLREGNWASVRTVLTGAVAL   180 
Canine 121 QVQEWMVAYLETRLADWIHSSGGWAEFTALYGDGALEEARRLREGNWASVRTVLTGAVAL   180 
Murine 121 QVQDWMVAYLETRLADWIHSSGGWAEFTALYGDGALEEARRLREGNWASVRTVLTGAVAL   180 
 
Human 181 GALVTVGAFFASK  193 
Canine 181 GALVTVGAFFASK  193 
Murine 181 GALVTVGAFFASK  193 
  
BH4 BH3 
BH1 
BH2 
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(Supplemental Figure S1 ctd.) 
 
 
Alignment for Mcl-1 
 
 
Human   1 MFGLKRNAVIGLNLYCGGAGLGAGSGGATRPGGRLLATEKEASARREIGGGEAGAVIGGS    60 
Canine   1 MFGLKRNAVIGLNLYCGGAGLGAGSGGASSSGGRLLASGKEATTRREGGGGEAGAVIGGS    60 
Murine   1 MFGLRRNAVIGLNLYCGGASLGAGGGSPA--GARLVA--EEAKARRE-GGGEA-------    48 
 
 
Human  61 AGASPPSTLTPDSRRVARPPPIGAEVPDVTATPARLLFFAPTRRAAPLEEMEAPAADAIM   120 
Canine  61 AGASPPTTLAPDARRVARPSPIGAEGPNVSATPPRLLLLAPPCRASPPEEMEGPAADAIM   120 
Murine  49 -------ALLPGARVVARPPPVGAEDPDVTASAERRLHKSPGLLAVPPEEMAASAAAAIV   101 
 
 
Human 121 SPEEELDGYEPEPLGKRPAVLPLLELVGESGNNTSTDGSLPSTPPPAEEEEDELYRQSLE   180 
Canine 121 SPEEELDGYEPEPLGKRPAVLPLLELVGEASSGPGMDGSLPSTPPPAEEEEDELYRQSLE   180 
Murine 102 SPEEELDGCEPEAIGKRPAVLPLLERVSEAAKSSGADGSLPSTPPPPEEEEDDLYRQSLE   161 
 
 
Human 181 IISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNE   240 
Canine 181 IISRYLREQATGAKDAKPLGGSRAASRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNE   240 
Murine 162 IISRYLREQATGSKDSKPLGEAGAAGRRALETLRRVGDGVQRNHETAFQGMLRKLDIKNE   221 
 
 
Human 241 DDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVR   300 
Canine 241 DDVKSLSRVIVHVFSDGVTNWGRIVTLISFGAFVAKHLKSINQESCIEPLAESITDVLVR   300 
Murine 222 GDVKSFSRVMVHVFKDGVTNWGRIVTLISFGAFVAKHLKSVNQESFIEPLAETITDVLVR   281 
 
 
Human 301 TKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR  350 
Canine 301 TKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR  350 
Murine 282 TKRDWLVKQRGWDGFVEFFHVQDLEGGIRNVLLAFAGVAGVGAGLAYLIR  331 
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(Supplemental Figure S1 ctd.) 
 
 
Alignment for Bak 
 
 
Human   1 MASGQGPGPPRQECGEPALPSASEEQVAQDTEEVFRSYVFYRHQQEQEAEGVAAPADPEM    60 
Canine   1 MASGQGPGPPRRECGEAAPSSTSEEQVARDTEEVFRSYVFYRHRQEQEAEGAAVPADPEM    60 
Murine   1 MASGQGPGPPKVGCDES--PSPSEQQVAQDTEEVFRSYVFYLHQQEQETQGAAAPANPEM    58 
 
  
Human  61 VTLPLQPSSTMGQVGRQLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATSLFE   120 
Canine  61 VTLPLEPSSTMGQVGRQLAIIGDDINQRYDSEFQAMLQHLQPTAENAYEYFTKIASSLFE   120 
Murine  59 DNLPLEPNSILGQVGRQLALIGDDINRRYDTEFQNLLEQLQPTAGNAYELFTKIASSLFK   118 
 
 
Human 121 SGINWGRVVALLGFGYRLALHVYQHGLTGFLGQVTRFVVDFMLHHCIARWIAQRGGWVAA   180 
Canine 121 SGINWGRVVALLGFGYRLALHVYQRGLTGFLGQVTRFVADFMLHHCIARWIAQRGGWVAA   180 
Murine 119 SGISWGRVVALLGFGYRLALYVYQRGLTGFLGQVTCFLADIILHHYIARWIAQRGGWVAA   178 
 
 
Human 181 LNLGNGPILNVLVVLGVVLLGQFVVRRFFKS  211 
Canine 181 LNLGNGPILNVLIVLSVVLLGQFVVRRFFKS  211 
Murine 179 LNFRRDPILTVMVIFGVVLLGQFVVHRFFRS  209 
 
 
 
Alignment for Bax var. alpha 
 
 
Human   1 MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLS    60 
Canine   1 MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGETPELPLEQVPQDASTKKLS    60 
Murine   1 MDGSGEQLGSGGPTSSEQIMKTGAFLLQGFIQDRAGRMAGETPELTLEQPPQDASTKKLS    60 
 
 
Human  61 ECLKRIGDELDSNMELQRMIAAVDTDSPREVFFRVAADMFSDGNFNWGRVVALFYFASKL   120 
Canine  61 ECLKRIGDELDSNMELQRMIAAVDTDSPREVFFRVAAEMFSDGNFNWGRVVALFYFASKL   120 
Murine  61 ECLRRIGDELDSNMELQRMIADVDTDSPREVFFRVAADMFADGNFNWGRVVALFYFASKL   120 
 
 
Human 121 VLKALCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGV   180 
Canine 121 VLKALCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGV   180 
Murine 121 VLKALCTKVPELIRTIMGWTLDFLRERLLVWIQDQGGWEGLLSYFGTPTWQTVTIFVAGV   180 
 
 
Human 181 LTASLTIWKKMG  192 
Canine 181 LTASLTIWKKMG  192 
Murine 181 LTASLTIWKKMG  192 
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(Supplemental Figure S1 ctd.) 
 
 
 
Alignment for Bad 
 
 
Human   1 ------------------------------------------MFQIPEFEPSEQEDSSSA    18 
Canine   1 ------------------------------------------MFQIPEFEPSEQEDSSPA    18 
Murine   1 MGTPKQPSLAPAHALGLRKSDPGIRSLGSDAGGRRWRPAAQSMFQIPEFEPSEQEDASAT    60 
 
 
Human  19 ERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQEQPTSSSHHGGAGAVEIRSRHSSYPA    78 
Canine  19 NRGLGPSPTGDRPPSPGKHQQTAPGLLGEAGHQQGQPASRKHHGGAGA-ETRSRHSSFPA    77 
Murine  61 DRGLGPSLTEDQP---GPY--LAPGLLGSNIHQQGRAATNSHHGGAGAMETRSRHSSYPA   115 
   
 
Human  79 GTEDDEGMGEEP-SPFRGRSRSAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGT   137 
Canine  78 GTDEDEGMEEEELSPFRGRSSSAPPNLCAARRYGRELRRMSDEFQGSF-KGLPRPKSAGT   136 
Murine  116 GTEEDEGMEEEL-SPFRGRSRSAPPNLWAAQRYGRELRRMSDEFEGSF-KGLPRPKSAGT   173 
 
 
Human  138 ATQMRQSSSWTRVFQSWWDRNLG--------  160 
Canine  137 ATQMRQSPSWTRVIQSWWDRNLGRGGSAPSQ  167 
Murine  174 ATQMRQSAGWTRIIQSWWDRNLGKGGSTPSQ  204 
 
 
Alignment for Noxa (PMAIP1) 
 
 
Human   1 -------------------------------------------------MPGKKARKNAQ    11 
Canine   1 -------------------------------------------------MPGRKARKSAQ    11 
Murine   1 MPGRKARRNAPVNPTRAELPPEFAAQLRKIGDKVYCTWSAPDITVVLAQMPGKSQKSRMR    60 
 
 
Human  12 -PSPARAPAELEVECATQLRRFGDKLNFRQKLLNLISKLFCSGT   54 
Canine  12 -PGPTRAPEELEVECAIQLRKFGDKLNFRQKLLNLLSKLFRSGT   54 
Murine  61 SPSPTRVPADLKDECA-QLRRIGDKVNLRQKLLNLISKLFNLVT  103 
 
 
 
 
 
 
Legend: 
Alignments are slightly modified from a CLUSTAL format alignment by MAFFT (v7.182) 
Non-identical amino acids are labelled in bold red; 
domains (labelled in gray): BH1, BH2, BH3, BH4 = Bcl-2 Homology Domain 1 to 4; TM = Transmembrane domain;  
MTD = Mitochondrial Targeting Domain; PS = phosphorylation site (Serine or Threonine residues) 
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PS 
